Diagnosis of Inflammatory Bowel Disease
ConditionInflammatory Bowel Disease (IBD)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorAssiut University
About this trial
* To quantify the expression of Nuclear enriched abundant transcript 1 (NEAT1) and Anti-sense Non RNA in the INLK4 locus (ANRIL) to determine their potential role as non invasive diagnostic biomarkers in inflammatory bowel disease. * To evaluate the correlation between the studied biomarkers and both the clinical presentation of the patients and the inflammatory mediators like Nuclear factor κB (NF-KB) signaling pathway.
Eligibility criteria
Qualifiers
Newly histopathologicaly diagnosed IBD
Disqualifiers
Patients with serious complications as intestinal obstruction, perforation, polyps or colorectal carcinoma
Patients who are taking NSAIDs or Immunosuppressive drugs
Patients who are having other autoimmune disorders
Patients with Chronic infections as TB or other diseases
Trial design
Treatments tested in this trial
- Not listed
Trial groups
62 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov